Related Experiment Video
Updated: Mar 26, 2026
Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells
Published on: February 21, 2014
Comprehensive Transcriptome Profiling Reveals Multigene Signatures in Triple-Negative Breast Cancer
Yi-Rong Liu1, Yi-Zhou Jiang1, Xiao-En Xu1
1Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, P.R. China. Cancer Institute, Fudan University Shanghai Cancer Center, Shanghai, P.R. China. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, P.R. China.
We developed a novel multigene signature integrating messenger RNAs (mRNAs) and long noncoding RNAs (lncRNAs) to predict outcomes for triple-negative breast cancer (TNBC) patients. This signature also identifies patients likely to benefit from taxane chemotherapy.
Area of Science:
- Oncology
- Genomics
- Molecular Biology
Background:
- Triple-negative breast cancer (TNBC) presents a significant clinical challenge due to limited targeted therapies.
- Accurate prognostic and predictive markers are crucial for effective individualized treatment strategies in TNBC.
Purpose of the Study:
- To develop and validate novel multigene signatures by integrating mRNA and long noncoding RNA (lncRNA) expression profiles.
- To facilitate individualized treatment decisions for triple-negative breast cancer patients.
Main Methods:
- Transcriptome microarrays were used to analyze 165 TNBC samples and 33 normal breast tissues.
- Tumor-specific mRNAs and lncRNAs were identified and correlated with recurrence-free survival (RFS).
- Cox regression models were employed to build and validate mRNA and integrated mRNA-lncRNA signatures.
Main Results:
- An integrated mRNA-lncRNA signature and an mRNA-only signature were successfully developed.
- Both signatures demonstrated significant prognostic value in predicting recurrence-free survival in training and validation sets.
- The integrated signature showed superior prognostic accuracy compared to the mRNA-only signature and clinicopathologic factors, and predicted favorable response to taxane chemotherapy.
Conclusions:
- The developed multigene signature accurately predicts clinical outcomes in TNBC patients.
- The signature can identify patients who will benefit from adjuvant taxane chemotherapy.
- This tool aids in personalized treatment strategies for triple-negative breast cancer.
